Evotec AG of Hamburg, Germany, has announced that it is collaborating with Active Biotech AB to identify small-molecule modulators of a priority biological target involved in immune disorders and cancer. The former, a drug discovery company, will use its technologies in assay development and high-throughput and surface plasmon resonance screening to identify and validate novel hits. It will screen its Lead Discovery Library, a small-molecule collection, to maximize the probability of finding medicinal chemistry starting points. Active Biotech of Lund, Sweden, develops pharmaceuticals for diseases of the immune system.